
AETHLON MEDICAL INC
AEMDNASDAQTrading Snapshot
- Day Range
- $3.15 β $3.22
- 52-Week Range
- $2.62 β $137.00
- Volume
- $2.98B
- Avg Volume
- $2.86B
- Shares Outstanding
- 2.6M
- Next Earnings
- Sep 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $570,003
- Last Q Revenue
- $136,184
- P/E Ratio
- β
- P/S Ratio
- 3.5x
- EPS (TTM)
- $-46.92
- Dividend Yield
- β
Why Investors Own AEMD
- βHigh-growth profile β revenue up -4.1% YoY with expanding US Equity exposure.
- βHealthy economics β 79% gross margin and 21% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AETHLON MEDICAL INC
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
AETHLON MEDICAL INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift AEMD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
AETHLON MEDICAL INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.